Development cooperation is an increasingly prominent focus in Chinese foreign diplomacy, and a central justification for Chinese firms’ engagement in large-scale land acquisitions (LSLAs) across the global South.
Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate continues on the decriminalisation, or even legalisation, of drugs, particularly cannabis. Models under development for the legal supply of cannabis are described in this analysis, as well as some of the questions they raise.
Part of the ‘Perspectives on drugs’ (PODs) series, launched alongside the annual European Drug Report, these designed-for-the-web interactive analyses aim to provide deeper insights into a selection of important issues.
The World Economic Forum’s Global Redesign Initiative is perhaps the best reflection of how corporations and other elites envision the future of governance. It calls for marginalising intergovernmental decision-making with a system of multi-stakeholder governance, but what does this mean for democracy, accountability and the rule of law?
We are proposing a binding mechanism to allow people access to medicines and hold Transnational Corporations (TNCs) responsible for violating a human right if they block their access. Intellectual Property Rights (IPR) is one of the pillars of global corporate power, that we are countering with the Global Campaign to Dismantle Corporate Power.
This is a guide to regulating legal markets for the non-medical use of cannabis. It is for policy makers, drug policy reform advocates and affected communities all over the world, who are witnessing the question change from, 'Should we maintain cannabis prohibition?' to 'How will legal regulation work in practice?
Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications.
Janet E. Joy, Stanley J. Watson, Jun Borras, Sebastian Scholl , John A. Benson, Wendy Wolford
01 January 1999
The medical use of marijuana is surrounded by a cloud of social, political, and religious controversy, which obscures the facts that should be considered in the debate. This book summarizes what we know about marijuana from evidence-based medicine--the harm it may do and the relief it may bring to patients. The book helps the reader understand not only what science has to say about medical marijuana but also the logic behind the scientific conclusions.
There is a growing body of evidence to support the use of medical cannabis as an adjunct to or substitute for prescription opiates in the treatment of chronic pain. When used in conjunction with opiates, cannabinoids lead to a greater cumulative relief of pain, resulting in a reduction in the use of opiates (and associated side-effects) by patients in a clinical setting. Additionally, cannabinoids can prevent the development of tolerance to and withdrawal from opiates, and can even rekindle opiate analgesia after a prior dosage has become ineffective.
The legal status of cannabis for personal use is one of the most controversial policy issues in the European Union. Although cannabis is a classified narcotic drug placed under control by the United Nations and by all EU Member States, the measures adopted to control it at national level vary considerably, as shown in the table, click here to access the information country by country.
The Executive Director of the UNODC, Mr Antonio Maria Costa, released a progress report, "Encouraging progress towards still distant goals", as a Contribution to the Mid-term (2003) Review of UNGASS. The report examines whether the international community is on track to reduce illicit drug production, trafficking and abuse. TNI reviewed the UN report.
This briefing is a preliminary sketch of the legal landscape for cannabis social clubs in Spain. Its author is presently conducting legal analysis and empirical research in Spain and her findings will be published in due course. The aim of this briefing is to provide an interim sketch of the relevant law for English speakers working in drug policy.
Benedikt Fischer, Victoria Jeffries, Wayne Hall, Robin Room, Elliot Goldner, Jürgen Rehm
01 September 2011
More than one in ten adults – and about one in three young adults – report past year cannabis use in Canada. While cannabis use is associated with a variety of health risks, current policy prohibits all use, rather than adopting a public health approach focusing on interventions to address specific risks and harms as do policies for alcohol. The objective of this paper was to develop ‘Lower Risk Cannabis Use Guidelines’ (LRCUG) based on research evidence on the adverse health effects of cannabis and factors that appear to modify the risk of these harms.
Philippe Lucas, Amanda Reiman, Mitch Earleywine, Stephanie K. McGowan, Megan Oleson, Michael P. Coward, Brian Thomas
19 November 2012
This article examines the subjective impact of medical cannabis on the use of both licit and illicit substances via self-report from 404 medical cannabis patients recruited from four dispensaries in British Columbia, Canada. The aim of this study is to examine a phenomenon called substitution effect, in which the use of one product or substance is influenced by the use or availability of another.
This article documents the rise of finance in food provisioning. It queries the role of financialization in the contemporary food crisis and analyzes its impacts upon power structures and the distribution of wealth within and along the agro-food supply chain.
The Sentencing Council for England and Wales initiated a consultation process in order to produce definitive sentencing guidelines for drugs offences for the UK in the future. In order to feed into this process, IDPC, in collaboration with TNI, held an Expert seminar on proportionality in sentencing for drug offences, on 20th May 2011, in London, UK. The seminar was an important gathering of international experts on the subject of proportionality and provided a space for fruitful and in depth discussions on sentencing experiences from around the world. A draft report of the meeting was sent to the Sentencing Council as part of the consultation process on 20th June.
Coca appears to be a useful treatment for various gastro-intestinal ailments, motion sickness, and laryngeal fatigue. It can be an adjunct in programs of weight reduction and physical fitness and may be a fast-acting antidepressant. It is of value in treating dependence on stronger stimulants.